Kevin Perge

Kevin Perge

Auto-generated profile, based on publicly available information

Kevin Perge

Hospices Civils de Lyon (HCL), Pediatric endocrinology Unit, Hôpital Femme Mère Enfant Université Claude Bernard Lyon 1 Lyon France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2022 in Reviews in Endocrine and Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
KPKevin Perge
Kevin Perge
MNMarc Nicolino
Marc Nicolino

5 March 2026 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
LLLucie Levaillant
Lucie Levaillant
NBNatacha Bouhours-Nouet
Natacha Bouhours-Nouet
FEFabienne Emeriau
Fabienne Emeriau
ADAurelie Donzeau
Aurelie Donzeau
SRStéphanie Rouleau
Stéphanie Rouleau
RCRegis Coutant
Regis Coutant
Backgound: The purpose of this study is to compare the effect of long-acting growth hormone (LAGH) to daily GH on body mass index (BMI) in children with growth hormone deficiency (GHD). Methods: We searched the PubMed database from its inception to July 2025 and identified three relevant randomized controlled trials lasting over 6 months, with extension phases providing longitudinal BMI data. Longitudinal BMI data were available for lonapegsomatropin, somatrogon, and somapacitan, but not for polyethylene glycol LAGH. Results: A total of 585 patients were included in the present analysis, of which 346 were in the LAGH group, and 239 were in the daily rhGH group, derived from seven original articles and two abstracts/ePosters. At 12 months, there was a significant difference in BMI SD scores between LAGH and daily GH groups (Mean difference [MD] 0.66 SDS [95% confidence interval [CI] 0.04–1.29]). BMI SDS significantly increased in the LAGH group (MD + 0.41 SDS [95% CI 0.04–0.77] from 0 to 12 months), whereas it did not change in the daily GH group (MD −0.35 SDS [95% CI −0.76 to +0.07] from 0 to 12 months). Between 12 and 24 months, after switching from daily GH to LAGH (daily GH/LAGH), or pursuing LAGH (LAGH/LAGH) in the extension phases of the studies, BMI SDS significantly increased in the daily GH/LAGH switching group (MD + 0.75 SDS [95% CI 0.24–1.27] from 12 to 24 months), whereas it remained steady in the LAGH/LAGH group. Omitting one study at a time from the meta-analysis did not materially affect the results. Conclusion: An increase in body mass index SD score is associated with the first year of LAGH use.

2 September 2020 in Molecular Syndromology
Verified
Journal Article
Closed access
PDF file
KPKevin Perge
Kevin Perge
MMMona Massoud
Mona Massoud
HGHélène Gauthier-Moulinier
Hélène Gauthier-Moulinier
OLOlivier Lascols
Olivier Lascols
NPNicolas Pangaud
Nicolas Pangaud
LPLinda Pons
Linda Pons
Donohue syndrome (leprechaunism; OMIM *246200) is a rare and often lethal autosomal recessive disease caused by mutations in the INSR gene. We report the case of a 29-year-old pregnant woman, primigravida, who was referred at 33 weeks of gestation for severe intrauterine growth restriction (IUGR). Ultrasound examination found severe IUGR associated with an obstructive hypertrophic cardiomyopathy (HCM), confirmed postnatally. The newborn’s blood glucose level fluctuated from fasting hypoglycemia to postprandial hyperglycemia. The infant was found to be homozygous for a novel missense pathogenic variant, c.632C>T (p.T211l), in exon 2 of the INSR gene, predicted to result in an abnormal insulin receptor. To our knowledge, this is the first report of leprechaunism being revealed by IUGR and HCM during the prenatal period. Clinicians should keep in mind that the association of these prenatal signs could indicate leprechaunism and specific early neonatal management could be proposed, in particular with recombinant human insulin-like growth factor-I.

20 January 2024 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
KPKevin Perge
Kevin Perge
ECEmilie Capel
Emilie Capel
CVCarine Villanueva
Carine Villanueva
JGJérémie Gautheron
Jérémie Gautheron
SDSafiatou Diallo
Safiatou Diallo
CVCorinne Vigouroux
Corinne Vigouroux
SOFT syndrome (MIM # 614813), characterized by Short stature, Onychodysplasia, Facial dysmorphism, and hypoTrichosis, is a rare primordial dwarfism syndrome caused by biallelic variants in POC1A, encoding a centriolar protein. SOFT syndrome, characterized by severe growth failure of prenatal onset and dysmorphic features, was recently associated with insulin resistance. This study aims to further explore its endocrinological features and pathophysiological mechanisms. We present clinical, biochemical, and genetic features of two unrelated patients carrying biallelic pathogenic POC1A variants. Cellular models of the disease were generated using patients’ fibroblasts and POC1A-deleted human adipose stem cells. Both patients present with clinical features of SOFT syndrome, along with hyperinsulinemia, diabetes or glucose intolerance, hypertriglyceridemia, liver steatosis and central fat distribution. They also display resistance to the effects of IGF-1. Cellular studies show that the lack of POC1A protein expression impairs ciliogenesis and adipocyte differentiation, induces cellular senescence, and leads to resistance to insulin and IGF-1. An altered subcellular localization of insulin receptors and, to a lesser extent, IGF1 receptors could also contribute to resistance to insulin and IGF1. Severe growth retardation, IGF-1 resistance, and centripetal fat repartition associated with insulin resistance-related metabolic abnormalities should be considered as typical features of SOFT syndrome caused by biallelic POC1A null variants. Adipocyte dysfunction, and cellular senescence likely contribute to the metabolic consequences of POC1A deficiency. SOFT syndrome should be included within the group of monogenic ciliopathies with metabolic and adipose tissue involvement, which already encompasses Bardet-Biedl and Alström syndromes.

29 June 2023 in Pediatrics
Verified
Journal Article
Closed access
PDF file
KPKevin Perge
Kevin Perge
LPLinda Pons
Linda Pons
NPNastassja Protsenko
Nastassja Protsenko
DCDelphine Collin-Chavagnac
Delphine Collin-Chavagnac
MNMarc Nicolino
Marc Nicolino
Monogenic obesity generally results in severe early-onset obesity associated with abnormal feeding behavior and endocrine disorders. We report here an extremely severe case of early-onset obesity associated with hyperphagia in an 11-month-old boy without other signs of a syndromic obesity. He developed severe obstructive sleep apnea, dyslipidemia, hepatic steatosis with cytolysis, and acanthosis nigricans with insulin resistance in the first months of life. Laboratory investigations showed an elevated serum leptin level (80.03 ng/mL, normal range 2.45–6.55 ng/mL). Next-generation sequencing of obesity genes panel identified a novel homozygous intronic variant in leptin receptor gene (LEPR), c.703 + 5G>A, predicting affected splicing that resulted in a frameshift, premature stop, and truncation of the protein beyond the cytokine receptor homology domain 1. The child died at 27 months of age in the absence of available specific drug therapy.

17 July 2024 in Reviews in Endocrine and Metabolic Disorders
Verified
Journal Article
Open access
PDF file
KPKevin Perge
Kevin Perge
ECEmilie Capel
Emilie Capel
VSValérie Senée
Valérie Senée
CJCécile Julier
Cécile Julier
CVCorinne Vigouroux
Corinne Vigouroux
MNMarc Nicolino
Marc Nicolino
SOFT syndrome (Short stature-Onychodysplasia-Facial dysmorphism-hypoTrichosis) is a rare primordial dwarfism syndrome caused by biallelic variants in POC1A encoding a centriolar protein. To refine the phenotypic spectrum of SOFT syndrome, recently shown to include metabolic features, we conducted a systematic review of all published cases (19 studies, including 42 patients). The SOFT tetrad affected only 24 patients (57%), while all cases presented with short stature from birth (median height: -5.5SDS([-8.5]-[-2.8])/adult height: 132.5 cm(103.5–148)), which was most often disproportionate (90.5%), with relative macrocephaly. Bone involvement resulted in short hands and feet (100%), brachydactyly (92.5%), metaphyseal (92%) or epiphyseal (84%) anomalies, and/or sacrum/pelvis hypoplasia (58%). Serum IGF-I was increased (median IGF-I level: + 2 SDS ([-0.5]-[+ 3])). Recombinant human growth hormone (rhGH) therapy was stopped for absence/poor growth response (7/9 patients, 78%) and/or hyperglycemia (4/9 patients, 45%). Among 11 patients evaluated, 10 (91%) presented with central distribution of fat (73%), clinical (64%) and/or biological insulin resistance (IR) (100%, median HOMA-IR: 18), dyslipidemia (80%), and hepatic steatosis (100%). Glucose tolerance abnormalities affected 58% of patients aged over 10 years. Patients harbored biallelic missense (52.4%) or truncating (45.2%) POC1A variants. Biallelic null variants, affecting 36% of patients, were less frequently associated with the SOFT tetrad (33% vs 70% respectively, p = 0.027) as compared to other variants, without difference in the prevalence of metabolic abnormalities. POC1A should be sequenced in children with short stature, altered glucose/insulin homeostasis and/or centripetal fat distribution. In patients with SOFT syndrome, rhGH treatment is not indicated, and IR-related complications should be regularly screened and monitored.PROSPERO registration: CRD42023460876.